GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

GeneDx Holdings Corp. (NASDAQ:WGS) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $87.4286.

Several equities research analysts have commented on the stock. Guggenheim reaffirmed a “buy” rating and issued a $74.00 price target (up from $70.00) on shares of GeneDx in a report on Monday, June 29th. Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. BTIG Research lowered their target price on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Finally, Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th.

Insider Buying and Selling

In other news, Director Casdin Capital, Llc bought 185,000 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average cost of $42.60 per share, with a total value of $7,881,000.00. Following the acquisition, the director directly owned 3,367,164 shares in the company, valued at $143,441,186.40. This trade represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Keith A. Meister bought 533,758 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was purchased at an average price of $37.86 per share, with a total value of $20,208,077.88. Following the completion of the purchase, the director owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. Insiders own 25.17% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. boosted its position in GeneDx by 30.6% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 381,725 shares of the company’s stock worth $49,647,000 after purchasing an additional 89,470 shares in the last quarter. SG Americas Securities LLC grew its holdings in GeneDx by 937.3% in the fourth quarter. SG Americas Securities LLC now owns 63,181 shares of the company’s stock valued at $8,217,000 after purchasing an additional 57,090 shares during the period. Goldman Sachs Group Inc. increased its position in shares of GeneDx by 4.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock valued at $158,738,000 after buying an additional 52,322 shares in the last quarter. Vanguard Group Inc. increased its position in shares of GeneDx by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock valued at $154,650,000 after buying an additional 18,647 shares in the last quarter. Finally, Renaissance Group LLC acquired a new position in shares of GeneDx during the 4th quarter worth approximately $7,167,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Stock Performance

WGS opened at $65.11 on Tuesday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx has a 12-month low of $32.21 and a 12-month high of $170.87. The firm has a 50 day moving average of $60.67 and a two-hundred day moving average of $69.94. The firm has a market capitalization of $1.93 billion, a PE ratio of -24.29 and a beta of 1.90.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The business had revenue of $102.25 million during the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period last year, the company earned ($0.23) earnings per share. On average, analysts anticipate that GeneDx will post -1 EPS for the current year.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Zacks Research upgraded GeneDx from “strong sell” to “hold,” indicating a less bearish view of the shares, although the rating does not represent a bullish recommendation. Zacks.com
• Neutral Sentiment: The numerous announcements largely repeat the same legal notice: investors who purchased GeneDx shares between April 16, 2025, and May 4, 2026, may apply to lead the lawsuit by August 3. The notices are investor-solicitation releases rather than new operational or financial developments. Rosen Law Firm deadline notice
• Negative Sentiment: Several firms, including Hagens Berman, Rosen Law Firm, Robbins Geller, Bragar Eagel & Squire, and others, confirmed or promoted a securities-fraud class action against GeneDx. The lawsuit alleges violations of federal securities laws and claims that the company made misleading statements regarding acquisition performance and related business prospects. Hagens Berman class action notice
• Negative Sentiment: One notice links the allegations to an asserted 49% stock decline, citing a reported $51 million acquisition expectation followed by a $31.2 million write-off within roughly 12 months. These allegations have not been proven in court, but the litigation creates potential legal costs, reputational risk, and uncertainty for shareholders. Kahn Swick and Foti class action notice

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.